ReviewSleep advances : a journal of the Sleep Research Society2026
Optimizing patient outcomes and empowering the patient-clinician partnership.
Review in Sleep advances : a journal of the Sleep Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment landscape for narcolepsy is rapidly evolving with the introduction of new therapies featuring unique mechanisms of action and innovative formulations of established treatments. The recent approval of a once-nightly sodium oxybate formulation (SO-ER) has expanded the spectrum of oxybate therapies to 3, including the traditional immediate-release formulation (OXB) and a low-sodium version containing calcium, magnesium, potassium, and sodium oxybates (LXB). While the availability of diverse options allows clinicians to tailor oxybate-based treatments, it also raises challenges in selecting and fine-tuning these therapies. Involving patients in the decision-making process through shared decision-making (SDM) platforms can be an effective approach to optimizing oxybate therapy. This review article aims to provide clinicians with a comprehensive overview of the unique characteristics of available oxybate formulations and potential strategies for delivering empathetic care that incorporates SDM into the selection and optimization of oxybate-based treatment regimens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.